Anticancer Drugs Practice Questions

Q: Which of the following drugs is not associated with significant cardiotoxicity?

Cisplatin. ***Cisplatin*** - While cisplatin is associated with various toxicities, including **nephrotoxicity** and **neurotoxicity**, significant **cardiotoxicity** (like cardiomyopathy or severe arrhythmias) is much less common compared to the other listed agents. - Its primary cardiac effects are often indirect, such as electrolyte disturbances, or less severe, making it the least cardiotoxic among the options. *5-Fluorouracil* - This drug is known to cause **coronary vasospasm**, leading to **angina** or **myocardial infarction** in some patients. - The cardiotoxicity can manifest as **ischemic events** and **arrhythmias**, particularly during or shortly after infusion. *Cyclophosphamide* - High doses of cyclophosphamide can induce **hemorrhagic myocarditis** and **congestive heart failure**, particularly in the setting of bone marrow transplantation. - It causes direct myocardial damage and can lead to rapid-onset cardiac dysfunction. *Doxorubicin* - Doxorubicin is a well-known cause of **dose-dependent cardiomyopathy**, which can lead to **irreversible heart failure**. - Its cardiotoxicity can be acute (arrhythmias, pericarditis-myocarditis syndrome) or chronic (dilated cardiomyopathy).

Q: Rituximab is used in all of the following conditions except:

Paroxysmal nocturnal hemoglobinuria. ***Paroxysmal nocturnal hemoglobinuria*** - **Eculizumab**, a C5 complement inhibitor, is the primary treatment for paroxysmal nocturnal hemoglobinuria to prevent complement-mediated hemolysis and thrombosis. - Rituximab targets CD20 B cells and would not directly address the underlying complement dysregulation in PNH. *Non-Hodgkin lymphoma* - Rituximab is a cornerstone of therapy, especially for **B-cell non-Hodgkin lymphomas**, as it targets the CD20 antigen expressed on malignant B cells. - It is often used in combination with chemotherapy regimens like **R-CHOP** (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). *Rheumatoid arthritis* - Rituximab is approved for the treatment of **moderate to severe rheumatoid arthritis** in patients who have had an inadequate response to TNF inhibitors. - It works by depleting B cells, which play a role in the autoimmune pathogenesis of RA. *Systemic lupus erythematosus* - While not officially FDA-approved for SLE, rituximab is used **off-label** in some severe, refractory cases of SLE, particularly those with significant renal or hematological involvement. - It targets B cells, which are central to autoantibody production and immune complex formation in SLE.

Q: Which chemotherapy drug functions by alkylating DNA, resulting in strand breaks and ultimately leading to cancer cell death?

Cyclophosphamide. ***Cyclophosphamide*** - **Cyclophosphamide** is an **alkylating agent** that forms covalent bonds with DNA, leading to DNA cross-linking and strand breaks. - This **DNA damage** prevents cell replication and triggers apoptosis in rapidly dividing cancer cells. *Methotrexate* - **Methotrexate** is an **antimetabolite** that inhibits **dihydrofolate reductase**, thereby blocking DNA synthesis. - Its primary mechanism is interfering with **folate metabolism**, not direct DNA alkylation. *Paclitaxel* - **Paclitaxel** is a **microtubule-stabilizing agent** that promotes microtubule assembly and prevents their disassembly. - This action blocks cell division during metaphase, but it does not involve DNA alkylation. *Vincristine* - **Vincristine** is a **vinca alkaloid** that inhibits microtubule formation by binding to tubulin. - This prevents the formation of the mitotic spindle, arresting cells in metaphase, and does not involve direct DNA modification.

Q: A patient receiving cisplatin for chemotherapy develops renal impairment. Which of the following drugs is least likely to cause nephrotoxicity?

Bleomycin. ***Bleomycin*** - **Bleomycin** is an antineoplastic agent known for its primary toxicity to the **lungs (pulmonary fibrosis)** and skin, with nephrotoxicity being very rare [1]. - Its mechanism of action involves DNA strand scission, but its elimination is primarily renal without causing significant damage to the **kidneys**. *Cisplatin* - **Cisplatin** is a highly nephrotoxic agent, causing acute tubular necrosis, and is a well-known cause of **renal impairment** in chemotherapy patients [2]. - The patient in the stem is described as receiving cisplatin and developing renal impairment, indicating its potent nephrotoxic potential. *Carboplatin* - **Carboplatin** is an analog of cisplatin and is also **nephrotoxic**, although its nephrotoxicity is generally less severe than that of cisplatin [2]. - It is still a significant concern, and regular monitoring of kidney function is required during treatment. *Methotrexate* - **Methotrexate**, especially at high doses, can cause **acute kidney injury** due to the precipitation of its metabolites in the renal tubules, leading to obstruction. - This nephrotoxicity can be mitigated by adequate hydration and **urinary alkalinization**.

Q: Hand and foot syndrome is caused by which of the following drugs?

5-Fluorouracil (5-FU). ***5-Fluorouracil (5-FU)*** - **Hand-foot syndrome (HFS)**, also known as palmar-plantar erythrodysesthesia, is a common and dose-limiting dermatological toxicity of 5-FU. - It presents with **redness, swelling, pain, and blistering** on the palms of the hands and soles of the feet. *Vincristine* - This drug is primarily associated with **neurotoxicity**, causing peripheral neuropathy with symptoms like paresthesias, weakness, and loss of reflexes. - It does not typically cause hand-foot syndrome, which is a specific dermatological reaction. *Cisplatin* - Cisplatin is known for its **nephrotoxicity** (kidney damage), ototoxicity (hearing loss), and severe nausea and vomiting. - While it can cause some dermatological side effects, hand-foot syndrome is not a characteristic or common adverse event associated with cisplatin. *Azathioprine* - Azathioprine is an immunosuppressant often used in autoimmune diseases and transplant patients, and its main side effects include **myelosuppression** (bone marrow suppression), liver dysfunction, and gastrointestinal issues. - It is not implicated in causing hand-foot syndrome.

Q: A patient with breast cancer is administered a chemotherapy agent that stabilizes microtubules, preventing their disassembly during mitosis. Which drug is used?

Paclitaxel. ***Paclitaxel*** - **Paclitaxel** is a **taxane** drug that works by binding to **beta-tubulin subunits**, stabilizing microtubules and preventing their depolymerization. - This stabilization arrests cells in the **G2/M phase of mitosis**, leading to apoptotic cell death in rapidly dividing cancer cells. *Doxorubicin* - **Doxorubicin** is an **anthracycline antibiotic** that intercalates into DNA, leading to strand breaks and inhibition of **topoisomerase II**. - Its primary mechanism is DNA damage, not direct microtubule stabilization. *Cyclophosphamide* - **Cyclophosphamide** is an **alkylating agent** that forms covalent bonds with DNA, causing cross-linking and strand breaks. - This DNA damage interferes with replication and transcription, leading to cell cycle arrest and apoptosis. *Vincristine* - **Vincristine** is a **vinca alkaloid** that binds to **tubulin dimers**, preventing their polymerization into microtubules. - Unlike paclitaxel, which stabilizes microtubules, vincristine inhibits their formation and promotes disassembly.

Q: Which enzyme is inhibited by the drug methotrexate during cancer treatment?

Dihydrofolate reductase. ***Dihydrofolate reductase*** - **Methotrexate** is a **folate analog** that competitively inhibits **dihydrofolate reductase (DHFR)**, an enzyme essential for converting dihydrofolate to **tetrahydrofolate**. - Inhibition of DHFR blocks the synthesis of **purine nucleotides** and **thymidylate**, thereby impairing DNA synthesis and cell proliferation, particularly in rapidly dividing cancer cells. *DNA polymerase* - **DNA polymerase** is involved in **DNA replication and repair**, but it is not the primary target of methotrexate. - While inhibition of DNA synthesis is an effect of methotrexate, it occurs upstream through the depletion of nucleotide precursors rather than direct inhibition of DNA polymerase. *Ribonucleotide reductase* - **Ribonucleotide reductase** is an enzyme responsible for converting **ribonucleotides to deoxyribonucleotides**, which are necessary for DNA synthesis. - While inhibiting this enzyme would also affect DNA synthesis, it is primarily targeted by drugs like **hydroxyurea**, not methotrexate. *Thymidylate synthase* - **Thymidylate synthase** is an enzyme that catalyzes the methylation of **deoxyuridylate (dUMP)** to **deoxythymidylate (dTMP)**, a crucial precursor for DNA synthesis. - While methotrexate ultimately reduces the supply of **N5, N10-methylenetetrahydrofolate**, a cofactor for thymidylate synthase, it does not directly inhibit the enzyme itself; rather, drugs like **5-fluorouracil** target this enzyme.

Q: A patient with HER2-positive breast cancer is resistant to trastuzumab. Which other targeted therapy could be considered?

Lapatinib. ***Lapatinib*** - **Lapatinib** is a dual tyrosine kinase inhibitor that targets both **HER1 (EGFR)** and **HER2**, providing an alternative mechanism of action that can be effective in some trastuzumab-resistant cases. - Its ability to inhibit the intracellular phosphorylation of these receptors helps to overcome resistance pathways that may develop with trastuzumab, which primarily targets the extracellular domain of HER2. *Bevacizumab* - **Bevacizumab** is a **monoclonal antibody** that targets **VEGF (vascular endothelial growth factor)**, inhibiting angiogenesis. - It is used in certain types of cancer but does not directly target HER2 or HER1 pathways, making it less effective for trastuzumab-resistant HER2-positive breast cancer. *Cetuximab* - **Cetuximab** is a monoclonal antibody that targets the **epidermal growth factor receptor (EGFR or HER1)**, but not HER2. - While it targets a related receptor, its specificity for HER1 means it would not be an appropriate choice for HER2-positive breast cancer, particularly in a trastuzumab-resistant setting. *Imatinib* - **Imatinib** is a **tyrosine kinase inhibitor** primarily used in **chronic myeloid leukemia (CML)** and **gastrointestinal stromal tumors (GIST)**. - It targets the **BCR-ABL fusion protein** and **KIT (CD117)**, which are not relevant therapeutic targets in HER2-positive breast cancer.

Q: Which chemotherapeutic agent is primarily associated with cardiotoxicity, particularly manifesting as dilated cardiomyopathy?

Doxorubicin. ***Doxorubicin*** - **Doxorubicin** is a well-known **anthracycline chemotherapeutic agent** with a significant risk of **dose-dependent cardiotoxicity**. - This cardiotoxicity primarily manifests as **dilated cardiomyopathy**, leading to progressive heart failure and ventricular dysfunction. *Vincristine* - **Vincristine** is a **vinca alkaloid** primarily associated with **neurotoxicity**, causing peripheral neuropathies, muscle weakness, and autonomic dysfunction. - While it can have some cardiac effects, **dilated cardiomyopathy** is not its primary or most common cardiotoxic manifestation. *Methotrexate* - **Methotrexate** is an **antimetabolite** primarily associated with toxicity to rapidly dividing cells, leading to **mucositis**, **myelosuppression**, and **hepatotoxicity**. - Although rare, it can cause pericardial effusion or myocarditis, but not typically **dilated cardiomyopathy**. *Cisplatin* - **Cisplatin** is a **platinum-based chemotherapeutic agent** primarily associated with **nephrotoxicity**, **ototoxicity**, and **neurotoxicity**. - While it can rarely cause electrolyte disturbances that indirectly affect cardiac function, **dilated cardiomyopathy** is not a primary or direct cardiotoxic effect.

Q: Which class of chemotherapy drugs inhibits the enzyme topoisomerase I, resulting in DNA damage and cancer cell death?

Topoisomerase I inhibitors. ***Topoisomerase I inhibitors*** - **Topoisomerase I inhibitors** like **irinotecan** and **topotecan** specifically target and inhibit **DNA Topoisomerase I**, preventing it from rejoining single-strand breaks. - This inhibition leads to the accumulation of **single-strand DNA breaks**, which are converted into lethal **double-strand breaks** during DNA replication, inducing **apoptosis** in cancer cells. *Vinca alkaloids* - **Vinca alkaloids** (e.g., **vincristine**, **vinblastine**) are **microtubule-targeting agents** that bind to **tubulin** and inhibit its polymerization, thus disrupting spindle formation during mitosis. - Their primary mechanism is **mitotic arrest** at the metaphase stage, not direct inhibition of topoisomerase enzymes. *Taxanes* - **Taxanes** (e.g., **paclitaxel**, **docetaxel**) are also **microtubule-targeting agents** that, unlike vinca alkaloids, stabilize microtubules and prevent their depolymerization. - This stabilization gums up the cell's machinery, leading to **mitotic arrest** and subsequent **apoptosis**. *Topoisomerase II inhibitors* - **Topoisomerase II inhibitors** (e.g., **etoposide**, **doxorubicin**) target and inhibit **DNA Topoisomerase II**, an enzyme that creates and reseals **double-strand DNA breaks**. - While they do cause DNA damage, their mechanism is distinct from Topoisomerase I inhibitors as they interfere with the religation step of **double-strand breaks**, not single-strand breaks.

Question 1

Which of the following drugs is not associated with significant cardiotoxicity?

Accepted Answer

Cisplatin

Answer

5-Fluorouracil

Answer

Cyclophosphamide

Answer

Doxorubicin

Question 2

Rituximab is used in all of the following conditions except:

Accepted Answer

Paroxysmal nocturnal hemoglobinuria

Answer

Rheumatoid arthritis

Answer

Systemic lupus erythematosus

Answer

Non-Hodgkin lymphoma

Question 3

Which chemotherapy drug functions by alkylating DNA, resulting in strand breaks and ultimately leading to cancer cell death?

Accepted Answer

Cyclophosphamide

Answer

Methotrexate

Answer

Paclitaxel

Answer

Vincristine

Question 4

A patient receiving cisplatin for chemotherapy develops renal impairment. Which of the following drugs is least likely to cause nephrotoxicity?

Accepted Answer

Bleomycin

Answer

Cisplatin

Answer

Carboplatin

Answer

Methotrexate

Question 5

Hand and foot syndrome is caused by which of the following drugs?

Accepted Answer

5-Fluorouracil (5-FU)

Answer

Vincristine

Answer

Cisplatin

Answer

Azathioprine

Question 6

A patient with breast cancer is administered a chemotherapy agent that stabilizes microtubules, preventing their disassembly during mitosis. Which drug is used?

Accepted Answer

Paclitaxel

Answer

Doxorubicin

Answer

Cyclophosphamide

Answer

Vincristine

Question 7

Which enzyme is inhibited by the drug methotrexate during cancer treatment?

Accepted Answer

Dihydrofolate reductase

Answer

DNA polymerase

Answer

Ribonucleotide reductase

Answer

Thymidylate synthase

Question 8

A patient with HER2-positive breast cancer is resistant to trastuzumab. Which other targeted therapy could be considered?

Accepted Answer

Lapatinib

Answer

Bevacizumab

Answer

Imatinib

Answer

Cetuximab

Question 9

Which chemotherapeutic agent is primarily associated with cardiotoxicity, particularly manifesting as dilated cardiomyopathy?

Accepted Answer

Doxorubicin

Answer

Methotrexate

Answer

Vincristine

Answer

Cisplatin

Question 10

Which class of chemotherapy drugs inhibits the enzyme topoisomerase I, resulting in DNA damage and cancer cell death?

Accepted Answer

Topoisomerase I inhibitors

Answer

Vinca alkaloids

Answer

Taxanes

Answer

Topoisomerase II inhibitors

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?